{"id":68096,"date":"2026-06-12T20:42:03","date_gmt":"2026-06-12T12:42:03","guid":{"rendered":"https:\/\/flcube.com\/?p=68096"},"modified":"2026-06-12T20:42:05","modified_gmt":"2026-06-12T12:42:05","slug":"junshi-biosciences-secures-global-exclusive-rights-to-cass-tetravalent-recombinant-dengue-vaccine-in-landmark-licensing-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68096","title":{"rendered":"Junshi Biosciences Secures Global Exclusive Rights to CAS&#8217;s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai Junshi Biosciences Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1877:HKG\">HKG: 1877<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688180:SHA\">SHA: 688180<\/a>), a China-based biopharmaceutical company, has struck a <strong>licensing agreement<\/strong> with the <strong>Institute of Microbiology (IM), Chinese Academy of Sciences (CAS)<\/strong>, securing <strong>global exclusive rights<\/strong> to the institution&#8217;s <strong>tetravalent recombinant dengue vaccine<\/strong>. The deal positions Junshi to develop and commercialize a next-generation dengue vaccine that addresses critical limitations of current live-attenuated approaches.<\/p>\n\n\n\n<h2 id=\"h-deal-structure-amp-intellectual-property\" class=\"wp-block-heading\">Deal Structure &amp; Intellectual Property<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensing Company<\/strong><\/td><td>Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180)<\/td><\/tr><tr><td><strong>Institution<\/strong><\/td><td>Institute of Microbiology (IM), Chinese Academy of Sciences (CAS)<\/td><\/tr><tr><td><strong>Rights Granted<\/strong><\/td><td>Global exclusive rights<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Tetravalent recombinant dengue vaccine<\/td><\/tr><tr><td><strong>Technology Type<\/strong><\/td><td>Recombinant protein-based (non-live)<\/td><\/tr><tr><td><strong>Target Coverage<\/strong><\/td><td>All four dengue virus serotypes (DENV1\u2013DENV4)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Preclinical\/early clinical (implied)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-vaccine-technology-amp-differentiation\" class=\"wp-block-heading\">Vaccine Technology &amp; Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform:<\/strong> <strong>Tetravalent recombinant vaccine<\/strong> \u2013 non-live, protein-based approach<\/li>\n\n\n\n<li><strong>Serotype Coverage:<\/strong> <strong>Simultaneously and evenly targets all four dengue virus serotypes<\/strong> (DENV1\u2013DENV4)<\/li>\n\n\n\n<li><strong>Key Advantages Over Live-Attenuated Vaccines:<\/strong><\/li>\n\n\n\n<li>Eliminates <strong>immune imbalance<\/strong> due to inter-serotype differences in growth and replication<\/li>\n\n\n\n<li>Reduces <strong>risk of severe disease through antibody-dependent enhancement (ADE)<\/strong><\/li>\n\n\n\n<li>Expands <strong>population applicability<\/strong> beyond current restrictions<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Provides <strong>comprehensive immune protection<\/strong> for populations at risk of dengue exposure<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Recombinant approach avoids risks associated with live viral vaccines<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-disease-context-amp-market-need\" class=\"wp-block-heading\">Disease Context &amp; Market Need<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Disease<\/strong><\/td><td>Dengue fever \u2013 acute vector-borne disease<\/td><\/tr><tr><td><strong>Causative Agent<\/strong><\/td><td>Dengue virus (four serotypes: DENV1\u2013DENV4)<\/td><\/tr><tr><td><strong>Transmission<\/strong><\/td><td>Primarily by Aedes mosquitoes (Aedes aegypti and Aedes albopictus)<\/td><\/tr><tr><td><strong>Global Burden<\/strong><\/td><td>Estimated 100-400 million infections annually worldwide<\/td><\/tr><tr><td><strong>Current Vaccines<\/strong><\/td><td>Limited options with significant safety and efficacy concerns<\/td><\/tr><tr><td><strong>Unmet Need<\/strong><\/td><td>Safe, effective vaccine suitable for broader population including seronegative individuals<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-strategic-implications\" class=\"wp-block-heading\">Competitive Landscape &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Market Leaders:<\/strong> Sanofi&#8217;s <strong>Dengvaxia<\/strong> (live-attenuated, restricted use in seronegative individuals) and Takeda&#8217;s <strong>Qdenga<\/strong> (live-attenuated, broader approval but still carries ADE concerns)<\/li>\n\n\n\n<li><strong>Technology Advantage:<\/strong> Recombinant approach potentially offers <strong>superior safety profile<\/strong> and <strong>broader population eligibility<\/strong><\/li>\n\n\n\n<li><strong>Global Opportunity:<\/strong> Dengue is endemic in over <strong>100 countries<\/strong> across Asia, Latin America, and increasingly in Europe and North America<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Multi-billion dollar market opportunity given high disease burden and limited current options<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-junshi-biosciences-strategic-positioning\" class=\"wp-block-heading\">Junshi Biosciences Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Expansion:<\/strong> Adds infectious disease vaccine to Junshi&#8217;s primarily oncology-focused pipeline<\/li>\n\n\n\n<li><strong>Technology Diversification:<\/strong> Demonstrates capability to develop and commercialize complex recombinant vaccines<\/li>\n\n\n\n<li><strong>Global Ambitions:<\/strong> Global exclusive rights support international development and commercialization strategy<\/li>\n\n\n\n<li><strong>Academic Partnership Model:<\/strong> Leverages China&#8217;s strong academic research institutions for innovative asset acquisition<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The collaboration between Junshi Biosciences and CAS is expected to accelerate the development of this promising vaccine candidate and bring new options for dengue prevention and control to global markets.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding development timelines, regulatory pathways, and commercial potential. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has struck&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[899,296,900,12],"class_list":["post-68096","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-1877","tag-junshi-biosciences","tag-sha-688180","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Junshi Biosciences Secures Global Exclusive Rights to CAS&#039;s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has struck a licensing agreement with the Institute of Microbiology (IM), Chinese Academy of Sciences (CAS), securing global exclusive rights to the institution&#039;s tetravalent recombinant dengue vaccine. The deal positions Junshi to develop and commercialize a next-generation dengue vaccine that addresses critical limitations of current live-attenuated approaches.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68096\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Secures Global Exclusive Rights to CAS&#039;s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal\" \/>\n<meta property=\"og:description\" content=\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has struck a licensing agreement with the Institute of Microbiology (IM), Chinese Academy of Sciences (CAS), securing global exclusive rights to the institution&#039;s tetravalent recombinant dengue vaccine. The deal positions Junshi to develop and commercialize a next-generation dengue vaccine that addresses critical limitations of current live-attenuated approaches.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68096\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-12T12:42:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-12T12:42:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68096#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68096\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Junshi Biosciences Secures Global Exclusive Rights to CAS&#8217;s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal\",\"datePublished\":\"2026-06-12T12:42:03+00:00\",\"dateModified\":\"2026-06-12T12:42:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68096\"},\"wordCount\":463,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 1877\",\"Junshi Biosciences\",\"SHA: 688180\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68096#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68096\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68096\",\"name\":\"Junshi Biosciences Secures Global Exclusive Rights to CAS's Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-12T12:42:03+00:00\",\"dateModified\":\"2026-06-12T12:42:05+00:00\",\"description\":\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has struck a licensing agreement with the Institute of Microbiology (IM), Chinese Academy of Sciences (CAS), securing global exclusive rights to the institution's tetravalent recombinant dengue vaccine. The deal positions Junshi to develop and commercialize a next-generation dengue vaccine that addresses critical limitations of current live-attenuated approaches.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68096#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68096\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68096#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Junshi Biosciences Secures Global Exclusive Rights to CAS&#8217;s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Secures Global Exclusive Rights to CAS's Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has struck a licensing agreement with the Institute of Microbiology (IM), Chinese Academy of Sciences (CAS), securing global exclusive rights to the institution's tetravalent recombinant dengue vaccine. The deal positions Junshi to develop and commercialize a next-generation dengue vaccine that addresses critical limitations of current live-attenuated approaches.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68096","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Secures Global Exclusive Rights to CAS's Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal","og_description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has struck a licensing agreement with the Institute of Microbiology (IM), Chinese Academy of Sciences (CAS), securing global exclusive rights to the institution's tetravalent recombinant dengue vaccine. The deal positions Junshi to develop and commercialize a next-generation dengue vaccine that addresses critical limitations of current live-attenuated approaches.","og_url":"https:\/\/flcube.com\/?p=68096","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-12T12:42:03+00:00","article_modified_time":"2026-06-12T12:42:05+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68096#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68096"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Junshi Biosciences Secures Global Exclusive Rights to CAS&#8217;s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal","datePublished":"2026-06-12T12:42:03+00:00","dateModified":"2026-06-12T12:42:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68096"},"wordCount":463,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 1877","Junshi Biosciences","SHA: 688180","Vaccine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68096#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68096","url":"https:\/\/flcube.com\/?p=68096","name":"Junshi Biosciences Secures Global Exclusive Rights to CAS's Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-12T12:42:03+00:00","dateModified":"2026-06-12T12:42:05+00:00","description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has struck a licensing agreement with the Institute of Microbiology (IM), Chinese Academy of Sciences (CAS), securing global exclusive rights to the institution's tetravalent recombinant dengue vaccine. The deal positions Junshi to develop and commercialize a next-generation dengue vaccine that addresses critical limitations of current live-attenuated approaches.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68096#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68096"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68096#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Junshi Biosciences Secures Global Exclusive Rights to CAS&#8217;s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68096"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68096\/revisions"}],"predecessor-version":[{"id":68097,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68096\/revisions\/68097"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}